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Abstract
 
In this report, we demonstrate that the Src homology 2 domain–containing inositol-5-phos-
phatase (SHIP) plays a critical role in regulating both B cell development and responsiveness to
antigen stimulation. SHIP
 
2
 
/
 
2
 
 mice exhibit a transplantable alteration in B lymphoid develop-
ment that results in reduced numbers of precursor B (fraction C) and immature B cells in the
bone marrow. In vitro, purified SHIP
 
2
 
/
 
2
 
 B cells exhibit enhanced proliferation in response to
B cell receptor stimulation in both the presence and absence of Fc
 
g
 
 receptor IIB coligation.
This enhancement is associated with increased phosphorylation of both mitogen-activated pro-
tein kinase and Akt, as well as with increased survival and cell cycling. SHIP
 
2
 
/
 
2
 
 mice manifest
elevated serum immunoglobulin (Ig) levels and an exaggerated IgG response to the T cell–
independent type 2 antigen trinitrophenyl Ficoll. However, only altered B cell development
was apparent upon transplantation into nonobese diabetic–severe combined immunodeficient
(NOD/SCID) mice. The in vitro hyperresponsiveness, together with the in vivo findings, sug-
gests that SHIP regulates B lymphoid development and antigen responsiveness by both intrinsic
and extrinsic mechanisms. 
Key words: signal transduction • B cell receptor • Fc
 
g
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response
 
Introduction
 
Src homology (SH)
 
1 
 
2 domain–containing inositol-5-phos-
phatase (SHIP) was initially identified as a 145- kD protein
that becomes tyrosine phosphorylated and associated with
Shc after stimulation of numerous cytokine receptors, as
well as the B cell receptor (BCR) and the TCR (1). The
cDNA was cloned independently by three groups, and was
found to encode a protein with an NH
 
2
 
-terminal SH2 do-
main, a central 5-phosphatase domain, two NPXY se-
quences that can bind phosphotyrosine domains when
phosphorylated, and a proline-rich COOH terminus (2–4).
Numerous smaller isoforms of SHIP, arising as a conse-
quence of both differential splicing and proteolytic diges-
tion, are detected in various cell populations depending on
the cell type and stage of maturation (5, 6). SHIP specifi-
cally recognizes and cleaves the 5
 
9
 
 phosphate group from
phosphatidylinositol–3,4,5-trisphosphate (PIP
 
3
 
), the prod-
uct of phosphatidylinositol 3-kinase (7) and, at least in
vitro, from inositol-1,3,4,5-tetrakisphosphate (3). 
Limited data exist regarding the expression of SHIP at
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Abbreviations used in this paper: 
 
BCR, B cell receptor; ERK, extracellu-
lar signal–regulated kinase; HF, HBSS containing 2% fetal bovine serum;
HSA, heat-stable antigen; MAPK, mitogen-activated protein kinase;
NOD, nonobese diabetic; PIP
 
3
 
, phosphatidylinositol-3,4,5-trisphosphate;
pre-B cell, precursor B cell; pro-B cell, progenitor B cell; RAG, recom-
bination activating gene; RFM, RPMI 1640 supplemented with 10% fe-
tal bovine serum, 2 mM glutamine, and 10
 
2
 
4 
 
b
 
-mercaptoethanol; SH, Src
homology; SHIP, SH2 domain–containing inositol-5-phosphatase; TI-2,
T cell–independent type 2. 
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various stages of B and T cell development. In the murine
thymus, SHIP expression can be detected by FACS
 
®
 
 in the
single positive CD4
 
1
 
 and CD8
 
1
 
 populations, and at a lower
level in the double positive population (8). Similar expres-
sion studies have also revealed the presence of SHIP in single
positive T cells isolated from human adult bone marrow,
suggesting that SHIP expression in the T cell lineage is
higher in more mature populations (9). In contrast, SHIP
appears to be expressed throughout B cell development in
both mice and humans, although the relative levels of ex-
pression have yet to be determined (8, 9). These observa-
tions suggest that SHIP may be important in B cell devel-
opment and in the function of both mature B and T cells.
In this regard, SHIP has been shown to play a major role
in the attenuation of BCR signaling (10, 11). Immune
complex binding coligates the BCR and the low-affinity
IgG receptor Fc
 
g
 
RIIB, resulting in a decrease in calcium
influx (12), decreased B cell proliferation (13, 14), and in-
creased apoptosis of mature B cell populations (15, 16).
Under these conditions, phosphorylated SHIP associates
with the immunoreceptor tyrosine–based inhibitory motif
of Fc
 
g
 
RIIB (17, 18). In addition, in vitro studies suggest
that SHIP becomes tyrosine phosphorylated, albeit to a
lesser extent, with BCR activation alone (19, 20). After ac-
tivation, SHIP associates with Shc and Grb2 to form a ter-
nary complex that may serve to localize SHIP to the plasma
membrane (21). Taken together, these biochemical studies
suggest that SHIP may be involved in both the activating
and inhibitory BCR signaling pathways.
Functional studies with the avian leukosis virus–trans-
formed bursal B cell line DT40 (22) provided initial in-
sights into the role of SHIP in B cells. Targeted disruption
of SHIP in these cells prevents the Fc
 
g
 
RIIB-mediated in-
hibition of calcium influx, suggesting that SHIP is the
dominant mediator of the negative signals associated with
Fc
 
g
 
RIIB coligation (10). Paradoxically, after coligation of
BCR and Fc
 
g
 
RIIB, these SHIP
 
2
 
/
 
2
 
 DT40 cells also exhibit
reduced proliferation and increased apoptosis (10) com-
pared with SHIP-expressing cells, despite enhanced phos-
phorylation and activation of the serine/threonine kinase
Akt (protein kinase B [23]). The DT40 cell line has also
been used to provide evidence that SHIP is involved in
regulating activation signals through the BCR. SHIP
 
2
 
/
 
2
 
DT40 cells demonstrate increased intracellular Ca
 
2
 
1 
 
levels
(24), increased membrane association of Btk (25), and en-
hanced Akt phosphorylation and activation (23) compared
with SHIP
 
1
 
/
 
1
 
 cells after BCR stimulation. These observa-
tions suggest that SHIP may play a critical role in establish-
ing the thresholds for BCR signaling under both activating
and inhibitory conditions.
Recombination activating gene (RAG) chimeric mice
generated with SHIP
 
1
 
/
 
2
 
 and SHIP
 
2
 
/
 
2 
 
embryonic stem
cells have been used as a starting point to further address
these issues in the context of primary B cells. In this model,
proliferation of mature SHIP
 
2
 
/
 
2
 
 B cells was greater than
SHIP
 
1
 
/
 
2
 
 B cells under inhibitory (intact antibody resulting
in Fc
 
g
 
RIIB coligation) conditions, but not after BCR acti-
vation with a F(ab
 
9
 
)
 
2
 
 fragment (26). This increased prolif-
 
eration correlated with enhanced levels of intracellular cal-
cium and increased mitogen-activated protein kinase (MAPK)
phosphorylation, consistent with the DT40 studies.
To examine the role of SHIP in vivo, we have carried
out targeted gene disruption using homologous recombi-
nation in embryonic stem cells (27). Mice bearing a ho-
mozygous deletion of SHIP are viable and fertile, but they
fail to thrive, and a significant mortality is observed by 14
wk of age. Consolidation of the lungs due to infiltration by
myeloid cells is a major contributing factor. These mice ex-
hibit a myeloproliferative disorder consistent with an en-
hanced responsiveness of myeloid progenitors to numerous
growth factors. This study suggests that SHIP is an impor-
tant negative regulator of cytokine signaling.
Intriguingly, our preliminary analysis suggested that the
numbers and percentages of B220
 
1
 
 cells in the bone mar-
row of these SHIP
 
2
 
/
 
2 
 
mice were reduced (27), as were
both the frequency and absolute number of progenitors ca-
pable of forming precursor B (pre-B) cell colonies in IL-7
containing methylcellulose. In contrast, T cell subsets
within the thymus appeared normal. These observations
prompted us to examine the consequences of SHIP defi-
ciency on immune function in greater detail.
In this paper, we report that SHIP deficiency leads to ab-
errant B cell development with a consequent decrease in
pre- and immature B cell pools in the bone marrow, and
increased B cell numbers in the spleen and lymph nodes.
Strikingly, serum Ig levels are elevated in SHIP
 
2
 
/
 
2
 
 mice,
and immunization with TNP-Ficoll, a T cell–independent
type 2 (TI-2) antigen, leads to an enhanced antibody re-
sponse. Thus, SHIP appears to play a role in limiting the
extent of the immune response to surface IgM–cross-link-
ing antigens. We also demonstrate that the alterations in B
cell development are transplantable to lymphoid-deficient
nonobese diabetic (NOD)/SCID recipients, and thus ap-
pear to be cell intrinsic. In contrast, both the elevations in
circulating Ig and the enhanced TI-2 response are abro-
gated after transplantation. These observations suggest that
SHIP plays a critical role in regulating the development and
antigen responsiveness of B lymphoid cells by both intrinsic
and extrinsic mechanisms.
 
Materials and Methods
 
Animals.
 
The generation of SHIP
 
2
 
/
 
2
 
 mice has been described
previously (27). All mice used in these experiments were F2 or F3
littermates (4–8 wk of age) that were bred and maintained with
sterilized food, water, and bedding in microisolator units at the
Joint Animal Facility of the British Columbia Cancer Research
Centre. Regular testing of sentinel animals was performed to en-
sure that the animal stocks were free of bacterial, viral, and para-
sitic infections. NOD/SCID mice (The Jackson Laboratory) were
bred and maintained as described above.
 
Flow Cytometry.
 
Bone marrow, spleen, or lymph node cells at
a density of 5–10 
 
3
 
 10
 
6
 
 cells/ml were incubated on ice for 30 min
with 4–6 
 
m
 
g/ml 2.4G2 (murine anti-IgG FcR antibody). Directly
conjugated FITC-, PE-, or cyanine 5 succinimidyl ester–labeled
antibodies were added, and incubations were continued on ice for
an additional 30–40 min. Cells were washed once in HBSS 
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(StemCell Technologies) containing 2% fetal bovine serum (HF)
at 4
 
8
 
C, and propidium iodide (Sigma Chemical Co.) at a concen-
tration of 1 
 
m
 
g/ml was included in the final wash. Cells were ana-
lyzed on a FACStar
 
PLUS™
 
 or FACSort™ (Becton Dickinson). All
antibodies used for these analyses were purchased from PharMin-
gen, with the exception of the anti-IgM and anti-IgD antibodies
that were from Southern Biotechnology Associates.
 
Expression Analysis by Reverse Transcription PCR and Global
cDNA Amplification.
 
Bone marrow and spleen cells were labeled
with the indicated antibodies as described above, and the various
B cell populations were collected using a FACStar
 
PLUS™
 
. Cells
were lysed with a guanidine isothiocyanate solution for isolation
of RNA, and reverse transcription and global cDNA amplification
were carried out using methods, described previously, that have
been shown to preserve the difference between frequent and rare
transcripts over a wide range of cell numbers (28).
Aliquots of the resulting cDNA populations were separated on an
agarose gel and passively transferred onto an ionic nylon membrane
(Zeta-Probe; Bio-Rad). Probes were labeled with [
 
32
 
P]dCTP
(3,000 Ci/mmol; Amersham Pharmacia Biotech) by random prim-
ing, and were purified on Sephadex G50 columns (Amersham Phar-
macia Biotech) before use. Blots were hybridized and washed as
described previously. Probes used in this study include the chicken
 
b
 
-actin cDNA and the 5
 
9
 
 SacI fragment of the SHIP cDNA (3).
PhosphorImager
 
®
 
 analysis using a Storm 860 PhosphorImager
 
®
 
and ImageQuant
 
®
 
 software (Molecular Dynamics) was used to de-
termine signal intensities for both actin and SHIP. The relative
level of SHIP expression was calculated by dividing the signal in-
tensity for SHIP by the signal intensity for actin. Results are shown
normalized to expression levels on the B220
 
1
 
c-kit
 
1
 
 population.
 
B Cell Purification.
 
Total spleen cells (pooled from three or
four mice) were resuspended to a density of 1 
 
3 
 
10
 
7
 
 cells/ml in
PBS solution (StemCell Technologies) supplemented with 2% fe-
tal bovine serum. Mature B cells were purified by negative selec-
tion using the StemSep™ (StemCell Technologies) magnetic
separation technique in accordance with the manufacturer’s in-
structions. Purity was confirmed by FACS
 
®
 
 analysis using anti-
bodies against B220, CD4, CD8, Mac-1, and Gr-1, and was gen-
erally 
 
.
 
85%.
 
Proliferation Assays.
 
A 50-
 
m
 
l aliquot of purified B cells (1 
 
3
 
10
 
5
 
) was added to triplicate wells of a 96-well plate (Falcon) in a
final volume of 200 
 
m
 
l RPMI 1640 (StemCell Technologies) sup-
plemented with 10% fetal bovine serum, 2 mM glutamine, and
10
 
2
 
4
 
 M 
 
b
 
-mercaptoethanol (RFM). Cultures were supplemented
with the indicated concentrations of goat anti–mouse IgM anti-
body (intact or F[ab
 
9
 
]
 
2
 
 fragment; Jackson ImmunoResearch Labo-
ratories) or 
 
Escherichia coli
 
 LPS (Sigma Chemical Co.). IL-4 was
supplied as a culture supernatant from the transfected cell line
X63114 (29), and the anti-CD40 antibody as a culture supernatant
from the FGK45 hybridoma (30). Cultures were incubated for
 
z
 
60 h before the addition of 1 
 
m
 
Ci of [
 
3
 
H]thymidine (New En-
gland Nuclear) for the final 6 h of incubation. Results represent
the mean 
 
6 
 
SD of triplicate wells.
 
Western Blot Analysis.
 
Purified wild-type and SHIP
 
2
 
/
 
2
 
 B cells
were resuspended at a density of 2 
 
3 
 
10
 
7
 
 cells/ml in RFM, and
were incubated with 20 
 
m
 
g/ml of goat anti–mouse IgM antibody
(either intact or the F[ab
 
9
 
]
 
2
 
 fragment) at room temperature for the
indicated amounts of time. Cells were washed once in PBS, and
were lysed at 5 
 
3 
 
10
 
7
 
 cells/ml at 4
 
8
 
C with 1% Triton X-100 in
phosphorylation solubilization buffer (50 mM Hepes, pH 7.4; 100
mM NaF; 10 mM Na
 
4
 
P
 
2
 
O
 
7
 
; 2 mM Na
 
3
 
VO
 
4
 
; 4 mM EDTA; 2
mM PMSF; 10 
 
m
 
g/ml leupeptin; and 2 
 
m
 
g/ml aprotinin). After
centrifugation, supernatants (total cell lysates) were subjected to
 
SDS-PAGE, and Western analysis was carried out using antiphos-
pho-MAPK or antiphospho-Akt antibodies as described previ-
ously (31). Blots were stripped and reprobed for Akt or MAPK to
control for the amount of protein loaded. Antiphospho-MAPK,
antiphospho-Akt, and anti-Akt antibodies were from New
England Biolabs, and anti–extracellular signal–regulated kinase
(ERK)-1 COOH-terminal antibodies were purchased from Up-
state Biotechnology.
 
Analysis of Cell Survival, Apoptosis, and Cell Cycling.
 
Purified
wild-type and SHIP
 
2
 
/2 B cells were resuspended at 2 3 105 cells/
ml in RFM with the indicated concentrations of goat anti–mouse
IgM antibody (intact or F[ab9]2 fragment), IL-4, or anti-CD40. At
various times, cultures were harvested, and the numbers of viable
and dead cells were determined microscopically using the vital
stain eosin. Cells were washed one time with HF, and were resus-
pended by vortexing in z100 ml of HF. 1 ml of ice-cold 70% eth-
anol was added dropwise while vortexing, and the cells were fixed
at 48C for at least 24 h before staining with propidium iodide at a
concentration of 10 mg/ml. The percentages of apoptotic and cy-
cling cells were determined by FACS® analysis using the FAC-
Sort™ and CELLQuest™ software (Becton Dickinson).
Determination of Serum Ig Levels. Serum Ig levels in SHIP2/2
mice and littermate controls were determined by ELISA. In brief,
ELISA 96-well plates were coated with goat anti–mouse Ig sub-
class–specific antibodies (Southern Biotechnology Associates), and
were incubated with serial dilutions of mouse serum. After 2 h,
the plates were washed with PBS, and were incubated for an addi-
tional 2 h with IgM-, IgG1-, IgG2a-, IgG2b-, and IgG3-specific
alkaline phosphatase–labeled goat anti–mouse antibodies (South-
ern Biotechnology Associates). The plates were washed, and the
presence of alkaline phosphatase was detected by the addition of
4-nitrophenyl phosphate. The OD was determined at 405 nm.
Calibrated mouse serum (The Binding Site) was used as a stan-
dard.
Antigenic Challenge of Wild-Type and SHIP2/2 Mice. Wild-
type and SHIP2/2 mice, 4–6 wk of age, were injected subcutane-
ously with 100 mg TNP-KLH in CFA (T cell dependent), or
were injected intravenously with 10 mg TNP-Ficoll (a gift from
P.J.L. Lane, University of Birmingham, Birmingham, UK) in PBS
(T independent). To elicit a secondary T cell–dependent immune
response, mice were challenged by intravenous injection of 10 mg
TNP-KLH in PBS at 35 d after the primary immunization. Serum
samples were collected at the indicated times, and serial dilutions
were incubated in 96-well ELISA plates coated with TNP-cou-
pled ovalbumin to detect TNP-specific antibodies using the pro-
tocol above. Antibody titers are expressed as the inverse serum
concentrations at the background OD 1 3SD.
Transplantation of NOD/SCID Mice. NOD/SCID mice, 6–8
wk of age, were intravenously injected with 1 3 107 bone mar-
row cells from SHIP1/1 or SHIP2/2 littermates. The engraftment
of donor-derived cells was assessed by FACS® analysis of periph-
eral blood cells for the presence of the Ly5.2 (CD45.2) cell surface
antigen. Dual staining of single cell suspensions from peripheral
blood, spleen, bone marrow, or lymph nodes with antibodies
against Ly5.2 and various lineage-specific antigens allowed an esti-
mation of the donor-derived contribution to lymphoid and my-
eloid cell compartments.
Results
Aberrant B Cell Development in SHIP2/2 Mice. Our initial
characterization of SHIP2/2 mice had revealed a reduction784 Role of SHIP in B Cell Development and Function
in both the percentage and number of B2201 cells in the
bone marrow of young (4–8-wk-old) animals. Bone mar-
row B cell development progresses through several stages
characterized on the basis of surface antigen expression and
Ig gene rearrangements, as well as responsiveness to stromal
interactions and IL-7 (32–37). Hematopoietic stem cells
give rise to B lymphoid–restricted progenitor B (pro-B)
cells that mature progressively to pre-B I cells (fractions
A–C), pre-B II cells (fractions C9 and D), and finally to imma-
ture (surface Ig–positive) and mature IgM1IgD1 B cells
(38, 39). To determine the stage(s) at which the perturba-
tions in B cell development occur in SHIP2/2 mice, we
carried out a more detailed FACS® analysis of bone mar-
row and peripheral B cell subsets.
Table I indicates, as our previous data showed (27), that
both the percentage and number of bone marrow B2201
cells are reduced in SHIP2/2 mice. Closer analysis reveals
that numbers of the earliest committed B2201CD431 B
cells (pro-B and pre-B I) are not reduced compared with
wild-type in either fraction A (heat-stable antigen [HSA]2)
or fraction B (HSA1). However, the BP-11CD431 cell
population (fraction C) is reduced to z50% of normal
numbers. Similarly, the pre-B II cell compartment defined
as B220loCD432IgM2 (fraction D) is slightly reduced in
both percentage and numbers in the marrow. Numbers of
B22021IgM1 B cells are reduced to z30%, whereas the
number of mature IgM1IgD1 B cells is reduced to z25%
of normal levels (Table I). Thus, the greatest decreases in
bone marrow B lymphocyte numbers in SHIP2/2 mice are
observed at the intermediate and late stages of B cell matu-
ration.
Further definition of the stage at which differences in B
cell development become apparent was achieved by limit-
ing dilution analysis of pre-B colony formation on an S17
stromal layer in the presence of IL-7 (40). Stromal cell and
IL-7 responsiveness is characteristic of the earliest B cell
progenitors (pro- and pre-B cells), although the require-
ment for both is lost in the transition to the small pre-B II
fraction (fraction D [32, 41]). Using this assay, the fre-
quency of pre-B colony-forming cells in the bone marrow
of SHIP2/2 mice was similar to that observed in wild-type
mice (1 in 216 compared with 1 in 258). Clonogenic B cell
Table I.  B Lymphoid Populations in 4–5-wk-old Wild-Type and SHIP2/2 Mice
Percentage of positive cells No. of positive cells
1/1 2/2 1/12 /2
3106 3106
Bone marrow (per femur)
B2201 31.9 6 2.7 20.2 6 2.2* 4.7 6 1.8 2.6 6 1.0
B220lo 24.4 6 3.4 16.3 6 1.7‡ 3.7 6 1.6 2.1 6 0.8
B220hi 7.6 6 1.5 3.9 6 1.2‡ 1.1 6 0.2 0.5 6 0.2‡
B2201CD431
HSA2 (fraction A) 3.7 6 2.1 3.6 6 1.7 0.5 6 0.3 0.5 6 0.3
HSA1 (fractions B and C) 4.9 6 1.9 6.4 6 1.1 0.8 6 0.5 0.8 6 0.3
BP-11CD431 (fraction C) 4.0 6 1.2 2.8 6 1.0 0.6 6 0.2 0.3 6 0.1
B220loCD432IgM2 (fraction D) 13.8 6 3.7 9.7 6 0.7 2.0 6 0.8 1.2 6 0.4
B2201IgM1 (fraction E) 6.8 6 3.8 6.3 6 4.1 1.1 6 0.9 0.8 6 0.7
B22021IgM1 (fraction F) 4.2 6 2.1 1.8 6 1.0 0.6  6  0.2 0.2  6  0.1
IgM1IgD1 5.9 6 1.3 3.9 6 1.3 0.8 6 0.1 0.2 6 0.1‡
Spleen
B2201 43.7 6 12.8 36.9 6 13.7 42 6 13 68 6 17
IgM1IgD1 36.3 6 8.4 33.9 6 7.3 63 6 23 109 6 17
Peripheral blood
IgM1IgD1 28.9 6 8.3 12.1 6 4.1‡ ND ND
Peritoneum
IgM1IgD1 31.6 6 2.8 16.8 6 1.3§ 1.0 6 0.1 1.85 6 0.1§
IgM1CD51 53.3 6 3.4 43.2 6 4.9 1.6 6 0.1 4.8 6 0.5§
Single cell suspensions, prepared from various tissues, were labeled with the indicated antibodies as described in Materials and Methods, and were
analyzed by FACS®. Values represent the mean 6 SD of three to four separate determinations. Statistical analysis was carried out using the Student’s
t test. 
*P # 0.01.
‡P # 0.05.
§P # 0.005.785 Helgason et al.
progenitors detected by colony formation in IL-7 contain-
ing methylcellulose culture, predominantly pre-B II or im-
mature B cells, were reduced by z50% in SHIP2/2 mouse
bone marrow, with absolute numbers per femur reduced to
30% of wild-type levels (27). These functional observations
are also consistent with a role for SHIP in the intermediate
stages of B cell development.
Peripheral B cell pools were examined by FACS® to de-
termine if the alterations in SHIP2/2 bone marrow com-
partments extended beyond the earliest stages of B lym-
phopoiesis. Surprisingly, the percentages of various B cell
populations present in the spleen (Table I) and lymph
nodes (data not shown) of SHIP2/2 mice were not signifi-
cantly altered. In fact, absolute numbers of splenic B2201
and IgM1IgD1 cells were slightly increased (1.6- and 1.7-
fold, respectively), reflecting the splenomegaly exhibited by
these young SHIP knockout mice. In contrast, the percent-
age of IgM1IgD1 mature B cells detected in the peripheral
blood was reduced by 40–50% compared with littermate
controls (Table I).
B-1a cells represent the predominant B cell population
within the peritoneal cavity, and appear to arise as a dis-
tinct B cell lineage generated from fetal and neonatal pro-
genitors (42, 43). Despite the reduced frequency of IgM1
IgD1conventional B cells, no significant difference was de-
tected in the percentages of IgM1CD51 B-1a cells found
in the peritoneal cavity of SHIP2/2 and wild-type mice
(Table I). However, as in the spleen, significantly more nu-
cleated cells are present in the peritoneum of SHIP2/2
mice (11.0 6 1.8 3 106 vs. 3.0 6 0.7 3 106 for SHIP2/2
and wild-type, respectively; P 5 0.006). Thus, there is a
consequent increase in absolute numbers of mature IgM1
IgD1 cells and B-1a cells compared with littermate controls
(Table I). These observations confirm that, despite reduced
numbers of bone marrow B lymphocytes, SHIP2/2 mice
have increased numbers of mature conventional B cells in
the spleen, lymph nodes, and peritoneum, as well as in-
creased numbers of CD51 B-1a cells in the peritoneal cavity.
Expression of SHIP in B Lymphoid Populations. Selected
B cell populations from the bone marrow and spleen were
examined to determine if SHIP mRNA expression corre-
lated with the stages at which B cell development shows the
greatest perturbations. As shown in Fig. 1, SHIP is ex-
pressed in all B cell populations examined, but at variable
levels. The highest relative expression levels are detected in
the B2201c-kit1 fraction of the bone marrow that corre-
sponds to the pro-B and pre-B cell pools (fractions A–C).
There is a progressive decrease in SHIP expression through-
out the remainder of the B cell developmental program
within the marrow. Expression in the B2201CD431 popu-
lation (intermediate to late pro-B cell stage) is reduced by
z50% compared with the expression in the earliest B cell
compartment. Although comparatively smaller, further de-
creases in SHIP expression occur in the transition from
pre-B to immature to mature bone marrow B cell. Thus,
the highest levels of SHIP mRNA expression are detected
in the earliest B cell progenitors.
Two B cell populations isolated from the spleen also
show dramatically different levels of SHIP mRNA expres-
sion. The IgM21IgD1 population, which corresponds to
the immature and marginal zone B cell pools (44, 45), ex-
presses levels of SHIP that approximate those observed in
the bone marrow B2201c-kit1 population. In contrast, the
follicular IgM1IgD1 population expresses lower levels of
SHIP than detected in any other B cell population. Thus, as
in the bone marrow, splenic B cells show a biphasic pattern
of SHIP mRNA expression, with the highest levels de-
tected in the less mature populations.
Enhanced Proliferative Responsiveness of SHIP2/2 B Cells.
Since SHIP has been postulated to play a negative role in
regulating B cell signaling (11), deficiency of this protein
might be expected to lead to enhanced or prolonged BCR
activation. The proliferative response of purified splenic
B2201 cells from SHIP2/2 mice incubated with an intact
anti-IgM antibody in the presence of 2.4G2 to block Fc-
gRIIB coligation led to significantly increased thymidine
incorporation compared with wild-type controls (Fig. 2 A).
Coligation of the BCR with FcgRIIB using intact antibody
alone significantly reduced the proliferation of wild-type B
cells, but not SHIP2/2 B cells, at all antibody concentra-
tions (Fig. 2 A). In addition, under coligation conditions,
the reduced proliferation of the wild-type cells correlated
Figure 1. Expression of SHIP in B cell subsets. (A) Southern blots of
amplified total cDNA prepared from phenotypically defined bone mar-
row and spleen B cell subsets, as well as total bone marrow (TBM), were
sequentially hybridized with probes specific for SHIP and actin as indi-
cated. (B) Signal intensities after hybridization were quantified by Phos-
phorImager® analysis, and expression levels of SHIP relative to actin were
calculated. Average expression levels from two determinations are shown
normalized to expression in the B2201c-kit1 population.786 Role of SHIP in B Cell Development and Function
with a decreased calcium influx (data not shown), whereas
no difference was observed with the SHIP2/2 cells. The en-
hanced proliferation of SHIP2/2 B cells in response to
BCR activation was also observed using the F(ab9)2 frag-
ment of goat anti–mouse IgM (Fig. 2 B), although only at
higher antibody concentrations. Analysis of calcium influx
under these conditions revealed no significant differences
between wild-type and SHIP2/2 B cells (data not shown).
To determine if the enhanced proliferative response was
restricted to stimulation through the BCR, 1/1 and 2/2
B cells were incubated with a variety of other reagents.
Wild-type and SHIP2/2 cells responded similarly to bacte-
rial LPS (Fig. 2 C) and either anti-CD40 or IL-4 alone (Fig.
2 D). However, SHIP2/2 B cells displayed an enhanced
proliferation in response to combinations of anti-CD40 plus
IL-4 (Fig. 2 E; data not shown). Together, these results
strongly implicate SHIP in the negative regulation of B cell
proliferative responses.
Increased Phosphorylation of MAPK and Akt in SHIP2/2 B
Cells. We sought to identify biochemical differences that
might underlie the enhanced proliferation of SHIP2/2 B
cells by assessing the phosphorylation of relevant proteins
after BCR stimulation with either the F(ab9)2 fragment or
intact goat anti–mouse IgM. For example, the ERKs p42
and p44 (ERK2 and ERK1), both members of the MAPK
family, are activated during signaling through the BCR
(46–48) and are well-established mediators of cell prolifera-
tion in many cell types (49, 50). Although BCR stimulation
induces MAPK phosphorylation in both wild-type and
SHIP2/2 cells, the SHIP2/2 cells exhibit higher levels of
MAPK phosphorylation at early times, especially when the
BCR is coligated with FcgRIIB using the intact antibody
(Fig. 3).
Elevations in PIP3 after BCR activation have been
shown to result in the phosphorylation and activation of
the survival factor Akt in B cells (23). Since SHIP has been
implicated in the regulation of Akt (51, 52), we examined
the phosphorylation of Akt in response to BCR signaling.
Coligation of BCR and FcgRIIB using an intact antibody
to mimic inhibitory signaling results in significantly higher
levels of Akt phosphorylation in the SHIP2/2 cells (Fig. 3).
Western blot analysis using the antiphosphotyrosine anti-
body 4G10 revealed that this enhanced tyrosine phosphor-
ylation of MAPK and Akt under coligating conditions is
specific, and is not due to a generalized increase in protein
phosphorylation (data not shown). Similarly, stimulation
Figure 2. Proliferation of purified B cells in response to various stimuli. (A) Purified splenic B cells from wild-type (d) or SHIP2/2 (r) mice were in-
cubated with intact goat anti–mouse IgM antibody in the presence (solid line) or absence (broken line) of the anti-FcR antibody 2.4G2 for 60 h before
addition of [3H]thymidine for determination of specific incorporation. Results are the mean 6 SEM of triplicate determinations (four experiments with
cells pooled from three or four mice per experiment). Purified splenic B cells from wild-type (d, solid line) and SHIP2/2 (r, broken line) mice were in-
cubated with various concentrations of the F(ab9)2 fragment of goat anti–mouse IgM antibody (B) or bacterial LPS (C), and proliferation was determined
as above. (D) Purified splenic B cells from wild-type (white bars) and SHIP2/2 (black bars) mice were incubated with the indicated concentrations of IL-4
or anti-CD40 culture supernatants. (E) Wild-type (d, solid line) and SHIP2/2 (r, broken line) B cells were incubated with 1% IL-4 supernatant and the
indicated percentages of anti-CD40 supernatant for determination of proliferation as indicated above. Statistical analysis between similarly treated wild-
type and SHIP2/2 cells was carried out using the Student’s t test. *P # 0.05; **P # 0.005.787 Helgason et al.
with the F(ab9)2 fragment also leads to increased phosphor-
ylation in the SHIP2/2 B cells, although to a lesser extent
(Fig. 3). These observations suggest that the enhanced acti-
vation of Akt and MAPK may contribute to the increased
proliferation of SHIP2/2 B cells by increasing survival, al-
tering the number of actively cycling cells, or increasing
the rate of progression through the cell cycle.
Survival, Apoptosis, and Cell Cycle Analysis. To gain fur-
ther insight into the mechanisms underlying the increased
proliferation of SHIP2/2 B cells, we examined cell viability,
and determined the proportion of cells in the apoptotic and
cycling fractions at various times throughout the 60-h incu-
bation period (Table II). Although the viability of freshly
isolated wild-type and SHIP2/2 B cells was similar as as-
sessed by eosin exclusion, the SHIP2/2 population con-
tained a larger apoptotic fraction as well as an increased
proportion of actively cycling cells. Regardless of the stim-
ulation used or the genotype of the cells, absolute numbers
of viable cells were reduced to z30% of input by 24 h.
At all time points examined, stimulation of wild-type B
cells with intact IgM reduced the proportion of viable cells
by approximately one half compared with treatment with
the F(ab9)2 fragment (Table II). In contrast, little difference
in the percentages of viable SHIP2/2 B cells was detected
under either condition. This observation alone may ac-
count for the enhanced proliferation of the SHIP2/2 B cells
under coligating conditions (Fig. 2 A). Indeed, there were
only slight differences between wild-type and SHIP2/2
cultures in the percentages of apoptotic and cycling cells at
any time point after stimulation with intact IgM antibody
(Table II).
Activation of the BCR using the F(ab9)2 fragment of IgM
does not result in significant differences between wild-type
and SHIP2/2 B cells at 24 or 48 h (Table II) for any of the
parameters examined. However, by 60 h, z50% of the wild-
type B cells are apoptotic, compared with only 20% of the
SHIP2/2 B cells. In addition, a slightly increased frequency of
the SHIP2/2 B cells were actively cycling. Taken together,
these observations may explain the modest increases observed
in [3H]thymidine incorporation by the SHIP2/2 B cells at this
F(ab9)2 fragment concentration (Fig. 2 B).
Finally, stimulation of wild-type and SHIP2/2 B cells
with anti-CD40 plus IL-4 resulted in increases both in cell
viability (at 48 and 60 h) and in the proportion of actively
cycling cells in the SHIP2/2 cultures at all time points ex-
amined (Table II). These observations are consistent with
Figure 3. Phosphorylation of Akt and MAPK after BCR stimulation of
purified B cells. Western blot analysis showing the time course of Akt
(Akt-P) and MAPK (p44-P and p42-P) phosphorylation in wild-type
(1/1) and knockout (2/2) B cells after BCR stimulation with the
F(ab9)2 (left) or intact (right) goat anti–mouse IgM. Protein levels of Akt
and MAPK are shown to indicate relative expression levels.
Table II. Analysis of Viability, Apoptosis, and Cell Cycle in Response to B Cell Stimulation
 
Percent viable 
(by dye exclusion) Percent apoptotic  Percent cycling 
Time 1/12 /21 /12 /21 /12 /2
h ,2n .2n
Unstimulated 0 95–98 95–98 0.35 6.7 13.2 21.7
IgM F(ab9)2 24 68.9 72.0 1.3 1.2 20.4 22.3
48 89.2 85.5 0.5 0.2 69.8 68.5
60 90.0 77.0 52.2 19.6 25.7 30.9
IgM intact 24 45.5 56.3 10.9 5.3 23.1 20.1
48 43.9 77.3 5.4 2.9 50.0 46.5
60 43.0 61.0 23.7 29.2 17.6 22.5
anti-CD40 1 IL-4 24 87.3 66.3 1.1 2.2 21.9 24.2
48 53.0 66.0 3.3 4.2 20.3 27.0
60 59.0 67.0 ND ND ND ND
Purified splenic B cells from wild-type and SHIP2/2 mice were stimulated with 10 mg/ml goat anti–mouse IgM (intact or F(ab9)2 or 5% anti-CD40
plus 1% IL-4 for the indicated amounts of time. Cell viability and cell cycle analysis were carried out as described in Materials and Methods. Results of
one representative determination are shown (n = 3).788 Role of SHIP in B Cell Development and Function
the increased proliferation of SHIP2/2 B cells in response
to this stimulation (Fig. 2 E).
Elevated Serum Ig and Enhanced Responsiveness to a TI-2
Antigen. The in vivo consequences of this enhanced B
cell responsiveness in SHIP2/2 mice were determined by
examining the circulating levels of Ig. SHIP2/2 mice have
significantly elevated levels of IgM, IgG2a, IgG2b, and
IgG3, whereas levels of IgG1 were marginally elevated
(Fig. 4). The magnitude of increase ranged from two- to
sevenfold, depending on the Ig isotype.
Inasmuch as SHIP deficiency increases the sensitivity of
mature B cells to BCR signaling, we examined the ability
of SHIP2/2 mice to respond to antigenic challenge. Mice
were challenged with the TI-2 antigen TNP-Ficoll, and
TNP-specific antibody titers were examined at 8 d after
immunization. SHIP2/2 mice exhibited a significantly in-
creased IgG, but not IgM, response to the antigen (Fig. 5
A). Surprisingly, the heterozygous mice showed an inter-
mediate enhancement in responsiveness. Further analysis of
the IgG isotypes revealed that IgG1, IgG2a, and IgG3 re-
sponses were all significantly elevated (z10–15 times for
each) compared with the wild-type controls (results not
shown). In contrast, SHIP2/2 mice and their littermate
controls responded similarly to the T cell–dependent anti-
gen TNP-KLH in both the primary and secondary chal-
lenges (Fig. 5 B). Thus, SHIP deficiency increases the Ig
production in response to a TI-2 antigen, but not to a T
cell–dependent antigen.
Altered B Cell Development, but Not TI-2 Hyperresponsive-
ness, Is Transplantable. One question arising from these
observations is whether the perturbations in B cell develop-
ment and function are solely intrinsic to the B cell popula-
tions, or whether they may also reflect alterations in acces-
sory cells. In an attempt to address this issue, total bone
marrow cells from wild-type or SHIP2/2 mice were trans-
planted into nonirradiated NOD/SCID mice. These mice
are immunodeficient, lack lymphoid cells, and show little
or no serum Ig with age (53). Under these conditions, it
was anticipated that the lymphoid populations would be
derived from the transplant, whereas the myeloid compart-
ment would be chimeric for both endogenous and trans-
planted cells.
Peripheral blood samples were examined at various times
from 7 wk to 7 mo after transplant for circulating levels of
total (B2201) and mature (IgM1IgD1) B cell populations.
NOD/SCID mice transplanted with bone marrow from
SHIP2/2 mice had significantly reduced levels of both B
cell populations (Fig. 6). In contrast, the percentage of do-
nor-derived cells expressing the Ly5.21 antigen was not
significantly different (69.2 6 23.9% for wild-type; 53.0 6
30.5% for SHIP2/2), suggesting, as observed in the knock-
out mouse, specific alterations in B cell development in the
absence of SHIP. Further examination revealed that the
percentage of donor-derived Mac-11Gr-11 cells in the pe-
ripheral blood was also similar (Fig. 6) in recipients of wild-
type and SHIP2/2 marrow. Importantly, there were no dif-
ferences in the cellularity of peripheral blood, spleen, or
bone marrow between recipients of wild-type and SHIP2/2
bone marrow. These observations, together with the ab-
sence of any detectable alterations in the proportion of my-
eloid cells in blood or other organs (see below), suggest that
transplanted nonirradiated NOD/SCID mice are a useful
model in which to examine the role of SHIP in B cell de-
velopment and immune function independent of the my-
eloproliferative syndrome.
A reduced frequency of B2201IgM1 cells was detected
in the bone marrow of SHIP2/2 transplant recipients at 7
mo after transplant (Table III; n 5 2). As in the peripheral
Figure 4. Serum Ig levels in 4–8-
wk-old SHIP wild-type (1/1),
heterozygous (1/2), and knock-
out (2/2) mice. Serial dilutions of
serum obtained from age-matched
mice (n 5 8–9) were used. Sym-
bols represent levels in individual
animals, and the bar represents
the mean value. Statistical analysis
was carried out using the Stu-
dent’s t test. *P # 0.05;  **P #
0.01; ***P # 0.005.789 Helgason et al.
blood, no significant differences were detected in the per-
centage of Ly5.21 donor-derived cells in the bone marrow.
This observation suggests a B cell–specific alteration in de-
velopment that occurs, as in the SHIP2/2 mouse, during
the intermediate stages of maturation. Surprisingly, signifi-
cant decreases in the frequency of B2201 and IgM1IgD1
populations in the spleen were also observed (Table III).
However, no obvious differences in the proportion of
Ly5.21 cells expressing B cell markers were detected (data
not shown), suggesting that the decrease in splenic B cells
merely reflects a decreased percentage of Ly5.21 cells in
this organ (Table III). No significant differences were ob-
served in the percentages of transplant-derived CD41,
CD81, or Mac-11Gr-11 cells in either the lymph nodes or
spleen (data not shown; Table III).
Serum Ig levels were analyzed to determine if the inap-
propriate elevations observed in SHIP-deficient mice were
transplantable. Surprisingly, as shown in Fig. 7 A, recipients
of wild-type and SHIP2/2 bone marrow cells displayed
similar levels of IgM and IgG. Thus, although the reduc-
Figure 5. Serum Ig levels after antigenic challenge. (A)
Anti-TNP–specific Ig levels before (d0) and 8 d (d8) after
immunization with the TI-2 antigen TNP-Ficoll. (B) Anti-
TNP–specific Ig at the indicated times after injection of the
T cell–dependent antigen TNP-KLH. Symbols represent
levels in individual animals, and the column represents the
mean value. Statistical analysis was carried out using the Stu-
dent’s t test. *P # 0.05.790 Role of SHIP in B Cell Development and Function
tion in bone marrow B cell numbers associated with the
absence of SHIP was transplantable, the elevation in serum
Ig levels was not.
We next examined whether bone marrow transplanta-
tion was sufficient to confer hyperresponsiveness to a TI-2
antigen. To address this question, five mice from each
transplant group that exhibited similar levels of Ly5.21
B2201 cells in the peripheral blood were challenged by in-
travenous injection of TNP-Ficoll. Mice transplanted with
cells of either genotype had similar basal levels of anti-TNP
antibodies (data not shown). However, in response to the
antigenic challenge, recipients of wild-type cells showed
increased anti-TNP titers of all IgG isotypes (Fig. 7 B) at 9
d after immunization. Surprisingly, the responsiveness of
mice transplanted with the SHIP2/2 bone marrow was sig-
nificantly impaired compared with that observed in recipi-
ents of wild-type marrow. Therefore, although the de-
creases in bone marrow B lymphopoiesis are transplantable,
the hyperresponsiveness to the TI-2 antigen is not. These
observations argue that SHIP plays a primary role in the
developmental B cell defect. However, the enhanced Ig
production by SHIP2/2 B lymphocytes may be the conse-
quence of altered accessory cell function.
Discussion
SHIP has emerged as a major regulatory molecule in both
lymphopoiesis and myelopoiesis. We have demonstrated
previously that targeted disruption of SHIP leads to a my-
eloproliferative disorder associated with pronounced lung
pathology and a shortened life span (27). In this report, we
demonstrate that SHIP deficiency has a profound effect on
both the generation and function of B lymphocytes. Our
analyses indicate that SHIP is required for normal prolifera-
tive responses to BCR stimulation, both in the presence and
absence of FcgRIIB coligation. Furthermore, SHIP plays a
pivotal role in regulating the normal serum Ig levels as well
as the antibody response to specific antigenic challenge.
Coligation of the BCR and FcgRIIB by antibody–anti-
gen immune complexes is one mechanism by which the
immune response is regulated. This cross-linking has been
shown to result in apoptosis of normal mature B cells (15,
16), but the molecular mechanisms underlying the inhibi-
tory nature of the FcgRIIB signal have only recently been
identified. Coligation induces the tyrosine phosphorylation
of FcgRllB at its intracellular immunoreceptor tyrosine–
based inhibitory motif sequences, with a consequent attrac-
tion of both SHIP and SH2 domain–bearing protein ty-
rosine phosphatase 1 (SHP-1) to the ligated receptor (18,
54). This results in a decrease in calcium influx and a de-
crease in the proliferative and survival signals within the B
cell. Studies using genetically altered chicken DT40 cells in-
dicate that SHIP, and not SHP-1, is the mediator responsi-
ble for this inhibitory signal (10). Our data showing an en-
Figure 6. B lymphocyte and myeloid populations in transplanted
NOD/SCID mice. FACS® analysis was carried out on peripheral blood
cells isolated from NOD/SCID mice transplanted with wild-type (d) or
SHIP knockout (r) bone marrow cells to determine the percentages of
cells expressing B220 or IgM plus IgD. Nontransplanted mice exhibited
undetectable levels of these markers (not shown). In addition, the per-
centages of transplant-derived cells expressing the Mac-1 and Gr-1 sur-
face antigens were determined (Ly5.21Mac1Gr1). Results are shown for
4–10 mice. Numbers above the column represent the mean 6 SD for
the indicated animals. Statistical analysis was carried out using the Stu-
dent’s t test. *P # 0.005.
Table III. FACS® Analysis of Selected Tissues from NOD/ SCID 
Mice Transplanted with Wild-Type or SHIP2/2 Bone Marrow Cells
Percentage of positive cells
1/12 /2
Bone marrow
Ly5.21 44.5 6 11.5 59.6 6 16.3
B2201 14.8 6 1.1 10.2 6 4.0
CD431B2201 3.0 6 0.9 2.6 6 0.1
IgM1B220lo 3.1 6 0.1 1.5 6 1.0*
IgM1B220hi 3.5 6 1.1 0.6 6 0.3‡
Spleen
Ly5.21 85.5 6 9.6 61.9 6 5.1
B2201 54.5 6 11.3 35.2 6 1.1*
IgM1IgD1 50.0 6 8.5 29.1 6 4.4*
Mac-11Gr-11 8.8 6 0.5 12.5 6 0.3
Lymph nodes
Ly5.21 99.3 6 0.1  86.2 6 12.7
B2201 36.1 6 0.1 40.7 6 6.1
IgM1IgD1 32.4 6 1.6 33.0 6 7.5
Mac-11Gr-11 12.4 6 8.4 3.0 6 0.7
Single cell suspensions, prepared from the various tissues, were labeled
with the indicated antibodies as described in Materials and Methods, and
were analyzed on a FACStarPLUS™. Values represent the mean 6 SD for
two determinations. Statistical analysis was carried out using the
Student’s  t test.
*P # 0.05.
‡P # 0.01.791 Helgason et al.
hanced proliferative response of SHIP2/2 splenic B cells to
IgM coligation argue that this also holds for primary murine
lymphoid cells. Increased phosphorylation of the serine/
threonine kinase Akt and MAPK (Fig. 3) may play a signifi-
cant role in this response. Indeed, at all time points exam-
ined, SHIP2/2 B cell cultures stimulated with intact anti-
IgM contained a higher percentage of viable cells (Table II),
suggesting that Akt phosphorylation enhances B cell sur-
vival. This observation contradicts the DT40 cell line stud-
ies, in which increased apoptosis and decreased proliferation
were observed in SHIP2/2 cells (10), perhaps reflecting dif-
ferences between primary B cells and B cell lines.
Positive stimulation through the BCR alone using F(ab9)2
anti-IgM antibody also induced an enhanced proliferative
response in B cells derived from the SHIP knockout mice,
which occurs with only slight increases in BCR-mediated
phosphorylation of Akt and MAPK (Fig. 3). There are also
no pronounced differences in cell survival, apoptosis, or cell
cycle status until later stages of the stimulation (Table II).
These observations suggest that alternative pathways may
play a more significant role in the enhanced proliferation of
SHIP2/2 B cells in response to BCR signaling. Indeed, the
explanation may reside in the recruitment and activation of
other signaling moieties. For example, antigen binding to
the BCR results in the activation of intracellular protein ty-
rosine kinases such as members of the Src family (i.e., Lyn),
Syk, and Btk (55, 56), with the consequent phosphorylation
of numerous proteins including SHIP, SHP-1, CD19, and
CD22. CD19 phosphorylation induces the association and
activation of phosphatidylinositol 3-kinase that is responsible
for the synthesis of PIP3, a substrate for SHIP. Prolonged el-
evations in PIP3 levels or alterations in the ratio of PIP3 to
PI-3,4-biphosphate have the potential to alter numerous
cellular functions regulating cell survival and proliferation
(57). The role of SHIP in regulating phosphoinositide levels
after BCR activation requires further investigation. How-
ever, whether it is through its phosphatase activity or its as-
sociation with other recruited proteins, SHIP may be re-
quired for regulating the intensity and duration of BCR
signaling. Thus, absence of SHIP might lead to changes in
gene transcription that could enhance proliferation and/or
decrease apoptosis over the long term. For example, it has
recently been shown that activation of Akt results in the
phosphorylation of a forkhead transcription factor, leading
to a transcription-dependent increase in cell survival (58).
The highest levels of SHIP expression within the B cell
compartment of the bone marrow were detected in the
most immature B cell subset (B2201c-kit1; Fig. 1). The ex-
tent to which these mRNA levels reflect protein expression
and which isoforms (5, 6) are predominant in each fraction
require further investigation. Regardless, the frequency and
number of cells in this immature population are not altered
in SHIP2/2 mice. Instead, differences are detected in the
more mature B cell compartments, suggesting that SHIP
plays an important role in regulating the normal develop-
mental transition from pre-B I to pre-B II cells. This pertur-
bation may be due to intrinsic alterations in responsiveness
to cytokine signals, as observed in the myeloid compartment
(27), or it may result from defects in the microenvironment.
For example, increased accumulations of myeloid cells may
alter the composition of the marrow sufficiently to interfere
with the generation and survival of these B cell populations.
Arguing against this, we also observed a reduced frequency
of mature B cells within the marrow of NOD/SCID mice
transplanted under conditions that favor the generation of
donor-derived lymphoid, but not necessarily myeloid, cells
(Table III). These observations suggest that the alterations in
B cell development are cell intrinsic. One intriguing possi-
bility is that the absence of SHIP leads to an accelerated dif-
ferentiation with a consequent reduction in the numbers of
immature bone marrow B cells. In support of this, SHIP2/2
Figure 7. Serum Ig and anti-TNP–specific antibody levels in NOD/
SCID mice transplanted with wild-type or SHIP2/2 bone marrow cells.
(A) Serum Ig levels were determined by ELISA measurements on serial
dilutions of serum taken from representative mice transplanted with wild-
type (d) or SHIP2/2 (r) bone marrow. (B) Nonirradiated NOD/SCID
mice with equivalent levels of Ly5.21B2201 cells in the peripheral blood
were injected intravenously with TNP-Ficoll, and serum samples were
collected 9 d after immunization. ELISAs were carried out to determine
the levels of anti-TNP–specific antibodies in recipients of wild-type (d)
or SHIP2/2 (r) bone marrow. Statistical analysis was carried out using
the Student’s t test. **P # 0.01; ***P # 0.005.792 Role of SHIP in B Cell Development and Function
mice have elevated numbers of mature B cells in both the
spleen (Table I) and the lymph nodes (not shown).
We and others (26) have now demonstrated, using in
vitro proliferation assays, that SHIP2/2 B cells do not re-
spond negatively to coligation of BCR and FcgRIIB. Thus,
it is likely that immune complex–mediated negative feed-
back on antibody production may also be drastically re-
duced in vivo. Indeed, SHIP2/2 mice display elevated se-
rum Ig levels (Fig. 4) and an enhanced Ig response to
immune challenge with the TI-2 antigen TNP-Ficoll (Fig.
5 A). In contrast to FcgRIIB-deficient mice that display an
enhanced Ig response to both T cell–dependent and T cell–
independent antigens (59), SHIP2/2 mice do not show an
enhanced antigenic response to TNP-KLH. This observa-
tion is confounded by the in vitro proliferation data indicat-
ing that SHIP2/2 B cells show an increased proliferation in
response to anti-CD40 plus IL-4 stimulation (Fig. 2).
Clearly, further analysis of B and T cell interactions in the
SHIP2/2 mice is required. However, the fact that SHIP2/2
mice are not globally hypersensitive to antigenic challenge
suggests that other pathways may be involved in the en-
hanced TI-2 response. Indeed, B cell responses to TI-2 anti-
gens are also dependent on various cytokines generated by
accessory cells (i.e., macrophages and mast cells [60]). Inas-
much as SHIP2/2 myeloid cells are hyperresponsive to cy-
tokine signaling (7, 27), it is possible that they also respond
more vigorously to the presence of antigen, leading to en-
hanced cytokine production that may play a role in the ele-
vated Ig levels. This possibility requires further investiga-
tion. However, the observations that NOD/SCID mice
transplanted with SHIP2/2 bone marrow do not exhibit a
disproportionate contribution to the myeloid compartment
(Table III) and do not show an enhanced Ig response to
TNP-Ficoll (Fig. 7) support the hypothesis that accessory
cells are a critical component of the hyperresponsiveness to
TNP-Ficoll.
Thus, all three murine models—the SHIP2/2 mouse and
the transplanted NOD/SCID mice described in this report,
as well as the SHIP2/2 RAG chimeric mice (26)—suggest
that SHIP plays a critical role in bone marrow B cell devel-
opment. Interestingly, it is debatable whether the enhanced
production of serum Ig is intrinsic or at least partially depen-
dent on external stimuli. Both the SHIP2/2 mice and the
RAG chimeras exhibit elevated Ig, although the isotypes af-
fected and the increases observed are variable, perhaps re-
flecting differences in cytokine levels regulating isotype
switching. The fact that NOD/SCID mice transplanted with
either wild-type or SHIP2/2 bone marrow cells display sim-
ilar Ig levels supports the hypothesis that the microenviron-
ment is involved in regulation of Ig production. Perhaps the
most striking difference among the three models is observed
in the responses to antigenic challenge. Both SHIP2/2 mice
(TNP-KLH) and SHIP2/2 RAG chimeric mice (vesicular
stomatitis virus [26]) respond similarly to T cell–dependent
antigenic challenge. Although the RAG chimeric mice were
not challenged with a TI-2 antigen, we observed that
SHIP2/2 mice exhibit an enhanced IgG response to TNP-
Ficoll compared with wild-type mice, whereas SHIP2/2
transplanted NOD/SCID mice are impaired in their re-
sponsiveness. These observations support the hypothesis that
B cell–extrinsic factors play an important role in the TI-2
response. A second possible explanation for the reduced re-
sponses of the SHIP2/2 cells in the NOD/SCID mice may
be an inability of the transplanted cells to form proper folli-
cles in the spleen and lymph nodes after immunological
challenge. Preliminary evidence suggests that the recipients
of SHIP2/2 cells have a deficiency of B cell–rich areas
within these organs (data not shown). Clearly, further inves-
tigation is required to examine the role of SHIP in regulat-
ing immune responses to antigenic challenge.
We have demonstrated previously that SHIP plays a piv-
otal role in myelopoiesis (27) and in the response of bone
marrow–derived mast cells to antigenic (61) and cytokine
(7) stimulation. In this report, we provide evidence that
SHIP is also an important regulator of B lymphocyte devel-
opment and immune function. As a consequence, young
SHIP2/2 mice exhibit a myeloproliferative disorder, ele-
vated Ig levels, and enhanced responses to specific antigenic
challenge. Numerous studies have demonstrated that lympho-
cyte hyperactivity correlates with an increased susceptibility to
autoimmune diseases (62, 63). Thus, the long-term conse-
quences of SHIP deficiency require careful examination.
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